See today's BioWorld Asia
To read the full story, subscribe or sign in.

Compugen reports phase I data for anti-PVRIG candidate

Dec. 13, 2022
By David Ho
At the ESMO Immuno-Oncology Congress 2022, Compugen Inc. shared phase I data for COM-701 in dual and triple combination with Bristol Meyers Squibb Co.’s Opdivo (nivolumab) and with or without BMS-986207.
BioWorld Asia Clinical Conferences European Society for Medical Oncology Cancer Asia-Pacific